Grab an Italian masterpiece for less

Vials of human blood have been grown from embryonic stem cells for the first time during research that promises to provide an almost limitless supply suitable for transfusion into any patient.
The achievement by scientists in the United States could lead to trials of the blood within two years, and ultimately to an alternative to donations that would transform medicine.
If such blood was made from stem cells of the O negative blood type, which is compatible with every blood group but is often in short supply, it could be given safely to anybody who needs a transfusion.
Stem-cell-derived blood would also eliminate the risk of transmitting the pathogens that cause hepatitis, HIV and Creutzfeldt-Jakob disease (CJD) through transfusions.
Scientists behind the advance said that it has huge therapeutic potential and could easily become the first application of embryonic stem-cell research to enter widespread clinical use. “Limitations in the supply of blood can have potentially life-threatening consequences for patients with massive blood loss,” said Robert Lanza, of Advanced Cell Technology (ACT) in Massachusetts, who led the experiments. “Embryonic stem cells represent a new source of cells that can be propagated and expanded indefinitely, providing a potentially inexhaustible source of red blood cells for human therapy. The identification of a stem cell line with O negative blood type would permit the production of compatible ‘universal donor’ blood.”
Blood comes in four groups, A, B, AB and O, and in two rhesus types, positive and negative, and only some of these are compatible with one another. A person with type A, for example, can donate to people with type A or AB, and receive blood of type A or O. Only O negative blood can be given to any patient.
While there is no national shortage of donated blood in Britain, O negative blood sometimes runs low. It is also used widely in military medicine.
The research also has more immediate clinical promise for efforts to turn embryonic stem cells into other types of tissue, to treat conditions such as diabetes and Parkinson’s.
One of the biggest safety hurdles that must be cleared before stem-cell therapies enter clinical trials is the risk of uncontrolled cell growth causing cancer. Red blood cells, however, do not have nuclei that carry the genetic material that goes wrong in cancer, and thus should not present this danger. “This could be one of the biggest breaks for the early clinical application of embryonic stem cells,” Dr Lanza said. “There is still work to be done, but we could certainly be studying these cells clinically within the next year or two.”
While a few red blood cells have been created from embryonic stem cells before, the ACT team is the first to mass-produce them on the scale required for medical use. They also showed that the red cells were capable of carrying oxygen, and that they responded to biological cues in similar fashion to the real thing. About two thirds had no nucleus, which suggests that they are fully fledged adult red blood cells, and the researchers hope to bring this closer to 100 per cent. Details of the research are published in the journal Blood.
Though embryonic stem cells were used in this experiment, it may be possible to create blood from reprogrammed adult cells, also known as induced pluripotent (IPS) cells. These would circumvent some ethical objections to the use of embryonic tissue.
Independent scientists welcomed the work. Professor Alex Medvinsky, a blood stem cell expert at the University of Edinburgh, said: “The problem with relying on donated blood is that there are always shortages. The ability to generate red blood cells in very large numbers would be a very big thing.”
Industry sectors news at a glance. Interactive heatmap, video and podcast
Everything the Business Traveller needs to know to make a better trip
Get ready for the winter sports season, with our resort guides and snow reports
We are backing British business, what is the confidence of the nation and what businesses are succeeding?
Growing demand for energy, oil that is harder to reach and the rise of carbon dioxide emissions. We examine the energy challenge
Enjoy further reading from Travel to Fashion, Business to Sport, discover more




Shortcuts to help you find sections and articles
1998
£47,955
12 months for the price of 11 and a 5% discount.
Offer ends 31/11/09
Check your free Experian credit report before applying
Car Insurance
to £60K + bonus (OTE £90k)
Lord Search & Selection
Location Flexible
If interested, call Oliver Luscombe on 0207 212 3065
PwC
£85k
CPA
Highly Competitve
Specsavers
Whiteley, near Southampton
Moments from Battersea Park.
For sale with Winkworth
Find out about shared ownership.
See your free Experian credit report beforehand
Book now & save over £100pp.
11 cool resorts, lowest prices... Early Booking offers 15 Nov.
20% off selected Azores holidays taken in October with Sunvil Discovery
Get covered on your travels with a superb range of policies at great prices. Visit InsureandGo.com
World Class Golf, Spa and preferential Beach Club. Private estate overlooking West Coast
Villas from £275 per night inclusive of Golf
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths | Subscriptions | E-paper
News International associated websites: Globrix Property Search | Milkround
Copyright 2009 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.